drugset / Trial / NCT07692451

Fosrolapitant and Palonosetron for the Prevention of Antibody-drug Conjugate-induced Nausea and Vomiting

NCT07692451

Phase 2 Not yet recruiting 124 enrolled Peking University Cancer Hospital & Institute
RandomizedParallel-groupQuadruple-blindPrevention

Summary

This study is aimed to evaluate the efficacy and safety of Fosrolapitant and Palonosetron for Antibody-drug conjugate-induced nausea and vomiting

Timeline

Start
2026-07-15
Primary completion
2027-07-15
Completion
2027-09-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Fosaprepitant Other / unclassified
Subject Fosrolapitant Small molecule
Subject Palonosetron Other / unclassified
Background Dexamethasone Small molecule